SonoLeukin (IL-2/Vesselon microbubble complex) / Vesselon - LARVOL DELTA

Merck Preclinical Study Reports 658% Increase in STING Agonist to Tumor When Used in Combination with Vesselon’s Drug (PRNewswire) - "A preclinical study, authored by Merck & Co., Inc. in collaboration with Vesselon, Inc., and published in Advanced Therapeutics in September 2021, reported a new, safe method for STING agonist delivery other than the limiting intratumoral approaches that have been used...Vesselon's acoustically active drug Imagent® augmented the pharmacokinetics of the STING agonist MSA-1 by increasing tumor uptake by 658%. When compared to a low MSA-1 intravenous dose that had no anti-tumor effect as a single agent, the addition of Imagent® under ultrasound exposure from conventional equipment generated complete tumor regressions...Vesselon plans to submit SonoLeukin™ INDs to improve the performance of Keytruda in recurrent, metastatic head and neck cancer as well as pancreatic cancer..."

Preclinical • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Pancreatic Cancer • Solid Tumor